Related Experiment Video
Updated: Jul 5, 2026
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
Treating patients with lupus with B-cell depletion
1Division of Medicine, Centre for Rheumatology, University College London, London, UK. d.isenberg@ucl.ac.uk
Lupus
|May 21, 2008
Summary
Monoclonal antibodies targeting CD20+ B cells offer a promising treatment for systemic lupus erythematosus. While open-label studies show effectiveness, results from double-blind controlled trials are anticipated.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Systemic lupus erythematosus (SLE) is a complex autoimmune disease.
- Current treatments often fail to manage refractory cases.
- Targeting key pathogenic molecules is a new therapeutic strategy.
Purpose of the Study:
- To review the efficacy of monoclonal antibodies in SLE treatment.
- To highlight the role of CD20+ B cell depletion in managing SLE.
- To emphasize the need for controlled clinical trials.
Main Methods:
- Review of existing literature on monoclonal antibody therapy in SLE.
- Analysis of open-label studies focusing on CD20 blockade.
- Discussion of the limitations of current evidence.
Main Results:
- Monoclonal antibodies targeting CD20+ B cells show significant potential.
- This approach is particularly effective in patients resistant to conventional therapies.
- Open-label studies indicate a favorable response profile.
Conclusions:
- CD20-targeted therapy represents a significant advancement in SLE treatment.
- Further rigorous investigation through double-blind controlled studies is crucial.
- This therapeutic avenue holds promise for improving patient outcomes in SLE.